5 Fastest Growing Health Tech Companies in the World
In this article, we will be taking a look at the 5 fastest growing health tech companies in the world.
Ascendis Pharma A/S (ASND)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 10,107,400 | $1,273,027,030 | -6% | 19.88% |
| 2. | VenBio Select Advisor Kurt Von Emster | 3,755,555 | $473,012,152 | +3% | 6.53% |
| 3. | 126,897,000 | $130,386,668 | +3% | 4.78% | |
| 4. | Vestal Point Capital Ryan Wilder | 625,000 | $78,718,750 | 8.33% | |
| 5. | Rock Springs Capital Management Kris Jenner, Gordon Bussard, Graham Mcphail | 290,000 | $36,525,500 | -32% | 0.89% |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,749,227 | $724,115,141 | 1.11% | |
| 2. | 5,114,369 | $644,154,776 | 0.04% | |
| 3. | 4,030,634 | $507,658,290 | 2.95% | |
| 4. | 3,994,785 | $503,101,502 | 0.3% | |
| 5. | 3,248,293 | $409,122,502 | 0.07% |
News See All
Ascendis Pharma A/S (ASND) Rose on Positive Trial Results
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” fourth-quarter investor letter. A copy of the same can be downloaded here.
30 Biggest Biotechnology Companies in the World
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world.
Ascendis Pharma A/S (ASND) Faced R&D Setbacks in Q4
Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here.
Ascendis Pharma A/S (NASDAQ:ASND) Q4 2023 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Fourth Quarter 2023 Ascendis Pharma Earnings Conference Call. At this time, all participants are in a listen-only mode.
Ascendis Pharma A/S (NASDAQ:ASND) Q3 2023 Earnings Call Transcript
Operator: Hello, and welcome to Ascendis Pharma Third Quarter 2023 Earnings Conference Call and Webcast.
Here’s What Caused the Volatility in Ascendis Pharma A/S (ASND)
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” second-quarter investor letter. A copy of the same can be downloaded here.
Ascendis Pharma A/S (NASDAQ:ASND) Q2 2023 Earnings Call Transcript
Operator: Hello, and welcome to Ascendis Pharma Q2 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Here’s Why Ascendis Pharma A/S (ASND) Declined in Q2
Artisan Partners, an investment management company, released its “Artisan Global Discovery Fund” second quarter 2023 investor letter. A copy of the same can be downloaded here.
15 Worst Performing Biotech Stocks in 2023
In this article, we discuss 15 worst performing biotech stocks in 2023.
Billionaire Hedge Funds
